Dimension Therapeutics, Inc. (DMTX) Aktienanalyse

Dimension Therapeutics, Inc. (DMTX) Gesundheitswesen & Pipeline-Uebersicht

Dimension Therapeutics, Inc. (DMTX) was a gene therapy company targeting rare diseases with a focus on liver-directed therapies. Though once promising, the company is no longer operational, rendering its historical financial data and development pipeline irrelevant for current investment considerations. The company's stock is no longer actively traded.

Investmentthese

Given that Dimension Therapeutics, Inc. was acquired by Ultragenyx Pharmaceutical Inc. in November 2017 and no longer exists as an independent entity, there is no active investment thesis to evaluate. Historical data indicates that the company was focused on developing gene therapies for rare diseases, particularly liver-directed treatments. At the time, potential value drivers included the advancement of their clinical programs, regulatory milestones, and successful commercialization of gene therapies. However, these factors are no longer relevant as the company is defunct. Investors interested in similar therapeutic areas should focus on Ultragenyx (RARE) or other companies actively developing gene therapies.

Basierend auf FMP-Finanzdaten und quantitativer Analyse

Wichtige Highlights

• Gross Margin was 100.0% indicating that the cost of goods sold was negligible compared to revenue, though the company's overall profitability was significantly impacted by high research and development expenses.
• Profit Margin was -427.2% reflecting substantial net losses due to the high costs associated with clinical trials and drug development.
• Beta of 4.18 indicating that the stock was highly volatile relative to the market, suggesting higher risk and potential reward (though this is no longer relevant as the company is defunct).
• The company did not pay any dividends, consistent with growth-stage biopharmaceutical companies that typically reinvest earnings into research and development.
• P/E Ratio was -3.04 reflecting the company's negative earnings, a common characteristic of biotech firms investing heavily in R&D before achieving profitability.

Wettbewerber & Vergleichsunternehmen

Staerken

• Proprietary AAV vector technology.
• Focus on liver-directed gene therapy.
• Expertise in rare disease drug development.

Schwaechen

• High R&D costs.
• Regulatory hurdles for gene therapy products.
• Competition from larger pharmaceutical companies.

Katalysatoren

• N/A - Dimension Therapeutics, Inc. no longer exists as an independent entity and therefore does not have any ongoing or upcoming catalysts.

Risiken

• N/A - Dimension Therapeutics, Inc. no longer exists as an independent entity and therefore does not have any ongoing or potential risks.

Wachstumschancen

• N/A - Dimension Therapeutics, Inc. no longer exists as an independent entity and therefore does not have any ongoing growth opportunities. Its assets and programs were integrated into Ultragenyx Pharmaceutical Inc. (RARE).
• N/A - Dimension Therapeutics, Inc. no longer exists as an independent entity and therefore does not have any ongoing growth opportunities. Its assets and programs were integrated into Ultragenyx Pharmaceutical Inc. (RARE).
• N/A - Dimension Therapeutics, Inc. no longer exists as an independent entity and therefore does not have any ongoing growth opportunities. Its assets and programs were integrated into Ultragenyx Pharmaceutical Inc. (RARE).
• N/A - Dimension Therapeutics, Inc. no longer exists as an independent entity and therefore does not have any ongoing growth opportunities. Its assets and programs were integrated into Ultragenyx Pharmaceutical Inc. (RARE).
• N/A - Dimension Therapeutics, Inc. no longer exists as an independent entity and therefore does not have any ongoing growth opportunities. Its assets and programs were integrated into Ultragenyx Pharmaceutical Inc. (RARE).

Chancen

• Expanding gene therapy applications to new diseases.
• Partnering with larger pharmaceutical companies.
• Securing regulatory approvals for gene therapy products.

Risiken

• Clinical trial failures.
• Adverse events associated with gene therapy.
• Competition from alternative therapies.

Wettbewerbsvorteile

• Proprietary AAV vector technology for liver-directed gene therapy.
• Patent protection for gene therapy products and methods.
• Expertise in gene therapy development and manufacturing.
• First-mover advantage in specific rare disease indications.

Ueber DMTX

Dimension Therapeutics, Inc., founded with the goal of developing innovative gene therapies, focused on addressing unmet needs in rare genetic diseases. The company's strategy centered around adeno-associated virus (AAV) vectors to deliver therapeutic genes directly to the liver, aiming for long-lasting treatment effects. Dimension Therapeutics pursued programs targeting hemophilia and other inherited metabolic disorders. Their approach involved advanced vector engineering and manufacturing processes to enhance safety and efficacy. Dimension Therapeutics, Inc. was acquired in November 2017 by Ultragenyx Pharmaceutical Inc. After the acquisition, Dimension Therapeutics, Inc. ceased to exist as an independent entity. The company's assets and programs were integrated into Ultragenyx's broader rare disease portfolio. Dimension Therapeutics, Inc. is no longer operational, and its stock is no longer actively traded.

Was das Unternehmen tut

• Developed gene therapies for rare diseases.
• Focused on liver-directed gene therapy using AAV vectors.
• Targeted hemophilia and other inherited metabolic disorders.
• Engineered advanced viral vectors for gene delivery.
• Conducted preclinical and clinical trials to evaluate safety and efficacy.
• Sought regulatory approval for their gene therapy products.
• Aimed to provide long-lasting therapeutic effects with single-dose treatments.

Geschaeftsmodell

• Focused on research and development of gene therapies.
• Out-licensed or partnered to commercialize therapies.
• Generated revenue through milestone payments and royalties.
• Sought funding through venture capital and public offerings.

Branchenkontext

Dimension Therapeutics, Inc. operated within the biopharmaceutical industry, specifically focusing on gene therapy for rare diseases. This sector is characterized by high research and development costs, lengthy regulatory approval processes, and significant market potential for successful therapies. The competitive landscape includes both large pharmaceutical companies and smaller biotech firms, all vying to develop innovative treatments for unmet medical needs. The gene therapy market is projected to experience substantial growth, driven by technological advancements and increasing investment in personalized medicine. Dimension Therapeutics aimed to capitalize on this trend with its liver-directed gene therapy platform before its acquisition.

Wichtige Kunden

• Patients with rare genetic diseases.
• Healthcare providers specializing in genetic disorders.
• Pharmaceutical companies interested in gene therapy collaborations.
• Payers (insurance companies and government healthcare systems).

Finanzdaten

Chart & Info

Aktuelle Nachrichten

Keine aktuellen Nachrichten fuer DMTX verfuegbar.

Analystenkonsens

MoonshotScore

Dimension Therapeutics, Inc. Aktie: Wichtige Fragen beantwortet

Haftungsausschluss: Dieser Inhalt dient ausschliesslich zu Informationszwecken und stellt keine Anlageberatung dar. Fuehren Sie immer Ihre eigene Recherche durch und konsultieren Sie einen Finanzberater.

Offizielle Ressourcen

Popular Stocks